Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 4
Submit an article Journal homepage
591
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant

Victor H. Jimenez-ZepedaTom Baker Cancer Center, Department of Medical Oncology and Hematology, Calgary, AB, Canada,
,
Peter DugganTom Baker Cancer Center, Department of Medical Oncology and Hematology, Calgary, AB, Canada,
,
Paola NeriTom Baker Cancer Center, Department of Medical Oncology and Hematology, Calgary, AB, Canada,
,
Ahsan ChaudhryTom Baker Cancer Center, Department of Medical Oncology and Hematology, Calgary, AB, Canada,
,
Karen MurrayTom Baker Cancer Center, Department of Medical Oncology and Hematology, Calgary, AB, Canada,
,
Marcia CulhamTom Baker Cancer Center, Department of Medical Oncology and Hematology, Calgary, AB, Canada,
,
Joanne LuiderCalgary Lab Services, Calgary, AB, Canada, and
,
Thomas FourieDepartment of Pathology and Laboratory Medicine, Foothills Medical Center, Calgary, AB, Canada
,
Fariborz Rashid-KolvearDepartment of Pathology and Laboratory Medicine, Foothills Medical Center, Calgary, AB, Canada
&
Nizar J BahlisTom Baker Cancer Center, Department of Medical Oncology and Hematology, Calgary, AB, Canada, Correspondence[email protected]
 show all
Pages 973-976 | Received 21 Apr 2015, Accepted 17 Aug 2015, Published online: 08 Oct 2015

References

  • Kumar L, Iqbal N, Mookerjee A, et al. Complete response after autologous stem cell transplant in multiple myeloma. Cancer Med 2014; 3: 939–946.
  • Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009; 114: 3139–3146.
  • Cavo M, Brioli A, Tacchetti P, et al. Role of consolidation therapy in transplant eligible multiple myeloma patients. Semin Oncol 2013; 40: 610–617.
  • McCarthy PL, Hahn T. Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. Hematology Am Soc Hematol Educ Program 2013; 2013: 496–503.
  • Lee SR, Kim SJ, Park Y, et al. Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. Korean J Hematol 2010; 45: 183–187.
  • Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.
  • Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
  • Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775–5782.
  • Harousseau JL, Avet-Loiseau H, Attal M, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 2009; 27: 5720–5726.
  • Barlogie B, Anaissie E, Haessler J, et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008; 113: 355–359.
  • Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–3076.
  • Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380.
  • Lonial S, Kaufman J, Tighiouart M, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res 2010; 16: 5079–5086.
  • Nishihori T, Alekshun TJ, Shain K, et al. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Br J Haematol 2012; 157: 553–563.
  • Roussel M, Moreau P, Huynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010; 115: 32–37.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.